# Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

> **NCT03365635** · PHASE4 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 6 (actual)

## Conditions studied

- Hepatitis C
- Hemodialysis
- Nosocomial Infection

## Interventions

- **DRUG:** Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]

## Key facts

- **NCT ID:** NCT03365635
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-22
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03365635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03365635, "Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03365635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*